Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Anticentriole antibody-positive limited cutaneous systemic sclerosis.

Nozaki H, Kishibe M, Kanno K, Igawa S, Saito T, Shimamura T, Minami-Hori M, Honma M, Ishida-Yamamoto A.

J Dermatol. 2017 Jun;44(6):e119-e120. doi: 10.1111/1346-8138.13754. Epub 2017 Feb 10. No abstract available.

PMID:
28186355
2.

A case of scleroderma spectrum disorder with anticentriole antibody and pulmonary hypertension.

Hayakawa I, Sato S, Hasegawa M, Echigo T, Takehara K.

Clin Rheumatol. 2004 Jun;23(3):266-8. Epub 2004 Apr 14.

PMID:
15168160
3.

Anticentriole antibody in a patient with progressive systemic sclerosis.

Osborn TG, Ryerse JS, Bauer NE, Urhahn JM, Blair D, Moore TL.

Arthritis Rheum. 1986 Jan;29(1):142-6. No abstract available.

PMID:
3511919
4.

Antibodies to centromere and centriole in scleroderma spectrum disorders.

Sato S, Fujimoto M, Ihn H, Takehara K.

Dermatology. 1994;189(1):23-6.

PMID:
8003781
5.

Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.

Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M.

J Rheumatol. 1986 Oct;13(5):911-6.

PMID:
3546686
6.

Anticentromere and anticentriole antibodies in the scleroderma spectrum.

Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M.

Arch Dermatol. 1983 Jul;119(7):560-6.

PMID:
6859899
7.

Anti-RNA polymerase III antibody-associated scleroderma renal crisis in a patient with limited cutaneous systemic sclerosis: A case report.

Takada D, Hoshino J, Kikuchi K, Yabuuchi J, Kogure Y, Ueno T, Sekine A, Yamanouchi M, Sumida K, Mise K, Suwabe T, Hayami N, Sawa N, Takaichi K, Hayasi N, Fujii T, Ohashi K, Ubara Y.

Mod Rheumatol. 2018 Mar;28(2):369-372. doi: 10.3109/14397595.2015.1112873. Epub 2016 Mar 4.

PMID:
26942857
8.

Expression of MMP-9 and TIMP-1 in lesions of systemic sclerosis and its implications.

Meng C, Chen X, Li J, Wu Y, Liu H.

J Huazhong Univ Sci Technolog Med Sci. 2008 Aug;28(4):480-2. doi: 10.1007/s11596-008-0424-y. Epub 2008 Aug 15.

PMID:
18704317
9.

A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.

Chang WS, Schollum J, White DH, Solanki KK.

Clin Rheumatol. 2015 Nov;34(11):1921-7. doi: 10.1007/s10067-015-2981-3. Epub 2015 May 29.

PMID:
26022620
10.

Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.

Hara T, Ogawa F, Muroi E, Komura K, Takenaka M, Hasegawa M, Fujimoto M, Sato S.

J Rheumatol. 2008 Mar;35(3):451-7. Epub 2008 Jan 15.

PMID:
18203319
11.

Assessment of Central Corneal Thickness in Different Subtypes of Systemic Sclerosis.

Gomes BA, Santhiago MR, Kara-Junior N, de Azevedo MN, Moraes HV Jr.

Ocul Immunol Inflamm. 2016 Dec;24(6):693-698. Epub 2015 Dec 11.

PMID:
26652214
12.

Significance of combined anti-CCP antibodies and rheumatoid factor in a New Zealand cohort of patients with systemic sclerosis.

Kamalaksha S, White DHN, Solanki KK.

Int J Rheum Dis. 2018 Jul;21(7):1430-1435. doi: 10.1111/1756-185X.13330.

PMID:
29968328
13.

Anti-PM-Scl antibody in patients with systemic sclerosis.

Koschik RW 2nd, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S12-6. Epub 2012 May 29.

PMID:
22261302
14.

Case of diffuse cutaneous systemic sclerosis with anti-Ku and anti-centromere antibodies.

Ohashi S, Ueda-Hayakawa I, Isei T, Okamoto H.

J Dermatol. 2013 Jul;40(7):558-61. doi: 10.1111/1346-8138.12148. Epub 2013 May 10.

PMID:
23663134
15.

Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.

Heickendorff L, Parvez A, Bjerring P, Halkier-Sørensen L, Zachariae H.

Acta Derm Venereol. 1991;71(3):185-8.

PMID:
1678217
16.

Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.

Srivastava N, Hudson M, Tatibouet S, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group (CSRG).

Semin Arthritis Rheum. 2015 Oct;45(2):184-9. doi: 10.1016/j.semarthrit.2015.04.009. Epub 2015 Apr 10.

PMID:
25959492
17.

Scleroderma renal crisis in a patient with anticentromere antibody-positive limited cutaneous systemic sclerosis.

Sugimoto T, Soumura M, Danno K, Kaji K, Kondo M, Hirata K, Nakazawa J, Uzu T, Nishio Y, Kashiwagi A.

Mod Rheumatol. 2006;16(5):309-11.

PMID:
17039313
18.

A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.

Mondini M, Vidali M, De Andrea M, Azzimonti B, Airò P, D'Ambrosio R, Riboldi P, Meroni PL, Albano E, Shoenfeld Y, Gariglio M, Landolfo S.

Arthritis Rheum. 2006 Dec;54(12):3939-44.

19.

[Clinical features of systemic sclerosis and association with antitopoisomerase-1 antibody and centromere pattern of antinuclear antibody].

Bertazzi GR, de Toledo RA, de Godoy MF, Geraldino GC, Polizelli DV, Fernandes GC, Pedroso CL, dos Santos FG, de Assis TM.

Acta Reumatol Port. 2012 Jan-Mar;37(1):9-17. Portuguese.

20.

Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis.

Marou E, Liaskos C, Simopoulou T, Efthymiou G, Dardiotis E, Katsiari C, Scheper T, Meyer W, Hadjigeorgiou G, Bogdanos DP, Sakkas LI.

Clin Rheumatol. 2017 Apr;36(4):863-869. doi: 10.1007/s10067-017-3553-5. Epub 2017 Jan 26.

PMID:
28124759

Supplemental Content

Support Center